TCGA-E2-A1B6-01A-31R-A12P-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.580
- INTERFERON_GAMMA_RESPONSE+0.560
- MYC_TARGETS_V2+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- E2F_TARGETS+0.290
- KRAS_SIGNALING_DN+0.280
- OXIDATIVE_PHOSPHORYLATION+0.240
- COMPLEMENT+0.200
- INFLAMMATORY_RESPONSE+0.200
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.480
- TGF_BETA_SIGNALING-0.470
- PROTEIN_SECRETION-0.460
- UV_RESPONSE_DN-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- MITOTIC_SPINDLE-0.380
- ANDROGEN_RESPONSE-0.340
- ANGIOGENESIS-0.290
- HEDGEHOG_SIGNALING-0.250
- GLYCOLYSIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.894 |
| 2 | SRR25617828 | — | D | 0.890 |
| 3 | TCGA-B6-A0I2-01A-11R-A034-07 | — | E | 0.886 |
| 4 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.883 |
| 5 | SRR9879287 | — | cohortA1 | 0.883 |
| 6 | TCGA-LL-A5YO-01A-21R-A28M-07 | — | D | 0.878 |
| 7 | SRR8518222 | — | D | 0.876 |
| 8 | TCGA-EW-A1OV-01A-11R-A144-07 | — | D | 0.868 |
| 9 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.854 |
| 10 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |